Cargando…
NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells
CCDC6 is implicated in cell cycle checkpoints and DNA damage repair by homologous recombination (HR). In NSCLC, CCDC6 is barely expressed in about 30% of patients and CCDC6 gene rearrangements with RET and ROS kinases are detected in about 1% of patients. Recently, CCDC6 point-mutations naming E227K...
Autores principales: | Cerrato, Aniello, Morra, Francesco, Di Domenico, Imma, Celetti, Angela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016757/ https://www.ncbi.nlm.nih.gov/pubmed/31877762 http://dx.doi.org/10.3390/cancers12010044 |
Ejemplares similares
-
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
por: Cerrato, Aniello, et al.
Publicado: (2016) -
Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors
por: Criscuolo, Daniela, et al.
Publicado: (2019) -
The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer
por: Cerrato, Aniello, et al.
Publicado: (2018) -
New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment
por: Criscuolo, Daniela, et al.
Publicado: (2019) -
The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells
por: Morra, Francesco, et al.
Publicado: (2017)